Page 1238 - Basic _ Clinical Pharmacology ( PDFDrive )

1224 Index

Major histocompatibility complex (MHC) Maprotiline, 540t, 542t, 546t, 547, 549, Melagatran, 617
molecules, 979f, 979–980 550t Melarsoprol, 934
Malaoxon, 116f Maraviroc, 872t, 882–883 Melatonin, 285f, 287b, 1143–1144
Malaria drugs, 917–928 Marfan syndrome, 305 Melatonin receptor
amodiaquine, 919f, 920t, 921 Marijuana, 581–582 agonists of, 394t
antibiotics case study of, 575, 589 in sleep-wake cycle, 384b
clindamycin, 927 G io protein-coupled receptor activation Meloxicam, 645t, 647
doxycycline, 920t, 927–928 by, 581, 582, 583f Melphalan, 953f, 955t. See also Alkylating
spiramycin, 928 Marinobufagenin, 217 agents
artemisinin, 919f, 920t, 922–923 Mast cell stabilizers, asthma treated with, Memantine, 1063
artesunate, 922–923 362t Membrane-delimited pathways, CNS,
artesunate-amodiaquine, 922t, Materia medica, 2 369f, 370
922–923 Maturation, female, estrogens on, 724 Membrane electrical activity, 229–230,
artesunate-sulfadoxine-pyrimethamine, Maximal efficacy, 36f, 36–37 230f
922t, 922–923 Maximal electroshock (MES) test, 409 Memory, 447b
atovaquone, 919f, 926 Maximum effect, on target concentration, Meningitis
atovaquone-proguanil, 920t 52 cephalosporin and vancomycin for, 795,
case study on, 917, 937 Maxzide, 266t 814
chemical structure of, 919f MDMA iatrogenic fungal, 859b
chemoprophylaxis and treatment of, acamprosate for dependence on, 589t Meningococcal vaccines
918, 920t–921t description of, 587 meningococcal conjugate, 1177t
chloroquine, 919f, 920t. See also Mean arterial pressure, 100, 102f meningococcal polysaccharide, 1177t
Chloroquine Measles, 1180t Menopause, 720
classification of, 917 Measles-mumps rubella (MMR) vaccine, Menotropins, 673–674
dihydroartemisinin-piperaquine, 922, 1177t Menstrual cycle, 720, 721f
922t Mebendazole, 939t, 942 Mentha pulegium extract, 1133t
folate synthesis inhibitors, 926 Mecamylamine, 133–134, 134f. See also Meperidine, 568, 572t. See also Opioid
fansidar, 926 Ganglion blockers agonists
proguanil, 919f, 926 Mecasermin, 672, 682t Mephenytoin, 419–420
pyrimethamine, 919f, 926 Mechlorethamine, 953, 953f, 955t. See also Mephobarbital, 393t. See also Barbiturates
sulfadoxine, 919f, 926 Alkylating agents Mepivacaine. See also Anesthetics, local
sulfadoxine-pyrimethamine, 920t Meclinertant, 314, 318t. See also description of, 460t, 462, 471
halofantrine, 919f, 920t, 928 Neurotensin antagonists G io protein-coupled receptor activation
lumefantrine, 919f, 920t, 928 Meclizine, 283t, 1106 by, 581, 583f
major, 919f, 920t Meclofenamate, 649 Mepolizumab, 357, 363t, 994
malarone, 920t, 926 Meclofenamic acid, 644f. See also Meprednisone, 709t. See also Corticoste-
mefloquine, 919f, 924–925 Nonsteroidal anti-inflammatory roids, synthetic
piperaquine, 919f, 920t, 922, 922t drugs (NSAIDs) Meprobamate, 383f, 392, 425f
preparations available, 936t Median effective dose (ED 50 ), 37, 37f Mequinol, 1076
primaquine, 919f, 920t, 925–926 Median lethal dose (LD 50 ), 13, 37, 37f Mercaptopurine, 71
quinidine, 923–924 Median toxic dose (TD 50 ), 37, 37f 6-Mercaptopurine (6-MP), 958t, 960–961,
quinine, 919f, 920t, 923–924 Medical pharmacology, 1 961f
in travelers, 920t Medicare, 1154 inflammatory bowel disease treated with,
for treatment, 922t Medroxalol, 166, 170t. See also b-receptor 1109–1110, 1116t
Malaria life cycle, 917, 918f antagonist drugs TPMT on metabolism of, 81
Malarone, 920t, 926 Medroxyprogesterone (acetate), 728, 728t. Mercurial diuretics, 262
Malathion, 116f, 122t, 1076. See also See also Progestins Mercury, 1027–1029
Organophosphate cholinesterase clinical uses of, 731 acute exposure to, 1029
inhibitors structure of, 729f chronic exposure to, 1029
Malignant hypertension, 190 Medullary depression, 446 history and epidemiology of,
Malignant hyperthermia, 288t Medullary-periventricular pathway, 516 1027–1028
anesthetics as cause of, 449, 483 Mefloquine, 919f, 924–925 intoxication with, 1028–1029
dantrolene for, 449, 488 Megakaryocyte growth factors, 604–605, pharmacokinetics of, 1021t, 1028
succinylcholine as cause of, 449, 483 606t treatment of, 1029
Malignant melanoma, 974–975 Megaloblastic anemia, 591, 607 Meropenem, 803t, 807, 812t
Managed care organizations, 1155 Megestrol acetate, 728, 728t. See also Mesalamine, 1107, 1116t
Manganese, 1017 Progestins Mescaline, 582–583
Mannitol, 267, 273t, 274t Meglitinide analogs, 759, 768t Mesna, 988